Dixon Hubard Feinour & Brown Inc. VA Acquires Shares of 3,000 Medtronic plc. (MDT)
Dixon Hubard Feinour & Brown Inc. VA acquired a new position in shares of Medtronic plc. (NYSE:MDT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,000 shares of the medical technology company’s stock, valued at approximately $242,000.
A number of other hedge funds also recently added to or reduced their stakes in the business. Griffin Asset Management Inc. raised its holdings in Medtronic by 9.5% during the fourth quarter. Griffin Asset Management Inc. now owns 33,260 shares of the medical technology company’s stock worth $2,686,000 after purchasing an additional 2,889 shares in the last quarter. Delek Group Ltd. acquired a new stake in Medtronic during the fourth quarter worth approximately $8,443,000. Sawtooth Solutions LLC acquired a new stake in Medtronic during the fourth quarter worth approximately $229,000. We Are One Seven LLC acquired a new stake in Medtronic during the fourth quarter worth approximately $104,000. Finally, HM Payson & Co. acquired a new stake in Medtronic during the fourth quarter worth approximately $965,000. 81.19% of the stock is currently owned by institutional investors.
A number of analysts have weighed in on the stock. Oppenheimer set a $94.00 price objective on shares of Medtronic and gave the stock a “buy” rating in a report on Friday, January 19th. Morgan Stanley raised their target price on shares of Medtronic from $91.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Monday, February 5th. Zacks Investment Research upgraded shares of Medtronic from a “sell” rating to a “hold” rating in a research report on Thursday, November 23rd. Jefferies Group restated a “buy” rating and set a $99.00 target price on shares of Medtronic in a research report on Thursday, November 23rd. Finally, Evercore ISI initiated coverage on shares of Medtronic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $92.50 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $91.50.
Medtronic plc. (NYSE MDT) opened at $78.14 on Friday. Medtronic plc. has a 1 year low of $76.51 and a 1 year high of $89.72. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.43 and a quick ratio of 2.09. The firm has a market cap of $108,294.30, a price-to-earnings ratio of 38.49, a P/E/G ratio of 2.27 and a beta of 0.97.
Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 20th. The medical technology company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.01. Medtronic had a net margin of 9.44% and a return on equity of 12.65%. The firm had revenue of $7.37 billion for the quarter, compared to analyst estimates of $7.20 billion. During the same period last year, the firm posted $1.12 EPS. Medtronic’s quarterly revenue was up 1.2% on a year-over-year basis. equities analysts anticipate that Medtronic plc. will post 4.75 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be given a $0.46 dividend. The ex-dividend date is Thursday, March 22nd. This represents a $1.84 dividend on an annualized basis and a yield of 2.35%. Medtronic’s dividend payout ratio (DPR) is 90.64%.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.